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We will test the hypothesis that aberrant expression of CDK9 and STAT3 in MB induces enhanced transcription
of oncogenic targets, leading to MB pathogenesis. Therefore, targeting both CDK9 and STAT3 function will
significantly decrease MB cell and tumor growth. To accomplish this hypothesis, we will first determine the
biophysical association of STAT3 and CDK9 in MB cells, and next, we will determine if combination of STAT3
knockdown and CDK9 inhibition has a significant effect on MB cell viability and STAT3 target gene expression.
Figure 4: Effect of STAT3 KD (A and B) in Dox (1 µg/ml) MB cells.
Figure 1: Schematic Diagram of CDK9 in STAT3-mediated gene expression. 
Figure 3: Endogenous interaction of STAT3 with CDK9 in IL-6 (50 ng/ml) dependent manner in (A) HD-MB03
(left) and ONS-76 cells (middle panel) by Co-Immunoprecipitation assay and by (B) Immunofluoresence assay
in 293 cells [3].
Figure 7: Effect of STAT3 knockdown and CDK9 inhibition on expression of oncogenic
targets (Western blot analysis).
HD-shSTAT3
Figure 2: Representative images of pSTAT3 (A and C) and CDK9 (B and D) expression in MB tumor,
performed by immunohistochemical staining (IHC) and Western Blot [4 & 5].
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Medulloblastoma (MB) is the most common primary malignant brain tumor of childhood. The current treatment
options for MB patients involves combination of surgical resection followed by high doses of radiation and
chemotherapy. However, these therapies are associated with risk for recurrence and serious neuro-cognitive
and endocrine sequelae, thereby warranting the immediate need of better treatment options. Our previous
study showed that Signal Transducer and Activator of Transcription factor- 3 (STAT3) and Cyclin dependent
Kinase -9 (CDK9) are overexpressed in MB and are correlated with poor prognosis. CDK9, an important
regulator of transcriptional elongation, is a major component of a complex known as the positive transcriptional
elongation factor b (P-TEFb). P-TEFb activates RNA Pol II by phosphorylating negative elongation factors and
serine 2 (Ser2) of the heptad repeat in the Pol II C-terminal domain (CTD) and thereby transitioning paused
RNA polymerase II to enter a productive transcriptional elongation mode. Both STAT3 and CDK9 are
considered as promising targets for cancer therapy, particularly for cancers driven by transcriptional
dysregulation. In this study, we aim to elucidate the role of CDK9 in STAT3-mediated MB pathogenies. We
have determined that CDK9 physically interacts with STAT3 in HD-MB03 (MYC-driven Group 3) and ONS-76
(SHH) MB cells. We observed that pharmacologic inhibition of CDK9 with Flavopiridol (FP) in STAT3
knockdown (KD) MB cells significantly decreases cell viability. Furthermore, combination of STAT3 KD and FP
treatment decreases protein expression of MYC and increases cleaved PARP, indicating its effect on inhibition
of proliferation and induction of apoptosis respectively. Combination of STAT3 KD and FP treatment also
decreases pSer2RNA Pol II expression, indicating inhibition of transcription elongation of a subset of STAT3
target genes. Therefore, the STAT3-CDK9 axis may serve as a potential therapeutic target in the treatment of
pediatric MB.
• CDK9 physically interacts with STAT3 in MB cells.
• Combined inhibition of CDK9 and STAT3 KD decreases MB cell viability significantly.
• Inhibition of both STAT3 and CDK9 decreases STAT3 target gene expression, including MYC.
• Combination of STAT3 KD and FP treatment also decreases pSer2RNA Pol II expression,
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Dox & FP Figure 6: Effect of CDK9 inhibition by FP(400 nM) and Dox (1 µg/ml) on STAT3
target gene expression.
